- Molecular NameLatanoprost
- Synonymlatanoprost
- Weight432.601
- Drugbank_IDDB00654
- ACS_NO130209-82-4
- Show 2D model
- LogP (experiment)4.027
- LogP (predicted, AB/LogP v2.0)4.23
- pkaN/A
- LogD (pH=7, predicted)4.23
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.53
- LogSw (predicted, AB/LogsW2.0)0.13
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds14
- TPSA86.99
- StatusFDA approved
- AdministrationTopical (eye drops)
- PharmacologyA topical medication used for controlling the progression of glaucoma or ocular hypertension by reducing intraocular pressure.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPrimarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation.
- Half life17 min
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include bloodshot eyes and eye irritation.
- LD50 (rat)N/A
- LD50 (mouse)N/A